Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cardiology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Trends in Readmissions Rates and Mortality after Cardiac Resynchronization Therapy in Patients with Nonischemic Cardiomyopathy

Abstract

Introduction

Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real-world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit.

Methods

We searched the National Readmissions Database (NRD) from 2016-2020 to identify hospitalizations with NICM using appropriate ICD-10 diagnosis and procedure codes. The cohort was further divided into groups with NICM and CRT-D implantation and NICM with CRT-P implantation.

Results

Our final cohort included 8,801 hospitalizations with NICM and CRT-D implantation and 3,399 hospitalizations with NICM and CRT-P implantation. Propensity matching was performed using comorbidities through multivariate logistic regression. Two thousand nine hundred seventeen hospitalizations were included in each of the two groups, CRT-D and CRT-P. Analysis of the propensity-matched cohorts at 180 days revealed a trend toward lower heart failure readmission, all-cause readmission, and all-cause mortality rates in the group with CRT-P implantation. However, there was no difference noted in the 180-day hazard ratios of HF readmission [1.08 (0.98-1.19); p = 0.1], all-cause readmission [1.04 (0.87-1.12); p = 0.23], and all-cause mortality [0.83 (0.58-1.19); p = 0.32].

Conclusion

It was found that NICM patients with CRT-D have a trend towards higher HF readmissions, all-cause readmission, and all-cause mortality compared to those with CRT-P, but no significant difference was noted in hazard ratios. The findings of our study raise further questions about the need for defibrillator therapy in patients with NICM and merit further studies to better select candidates for each of these therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X345244250217052010
2025-03-03
2025-04-08

  • From This Site

    /content/journals/ccr/10.2174/011573403X345244250217052010
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. van Walraven C. Jennings A. Forster A.J. A meta‐analysis of hospital 30‐day avoidable readmission rates. J. Eval. Clin. Pract. 2012 18 6 1211 1218 10.1111/j.1365‑2753.2011.01773.x 22070191
    [Google Scholar]
  2. Heidenreich P.A. Albert N.M. Allen L.A. Bluemke D.A. Butler J. Fonarow G.C. Ikonomidis J.S. Khavjou O. Konstam M.A. Maddox T.M. Nichol G. Pham M. Piña I.L. Trogdon J.G. American Heart Association Advocacy Coordinating Committee Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Radiology and Intervention Council on Clinical Cardiology Council on Epidemiology and Prevention Stroke Council Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ. Heart Fail. 2013 6 3 606 619 10.1161/HHF.0b013e318291329a 23616602
    [Google Scholar]
  3. Virani S.S. Alonso A. Benjamin E.J. Bittencourt M.S. Callaway C.W. Carson A.P. Chamberlain A.M. Chang A.R. Cheng S. Delling F.N. Djousse L. Elkind M.S.V. Ferguson J.F. Fornage M. Khan S.S. Kissela B.M. Knutson K.L. Kwan T.W. Lackland D.T. Lewis T.T. Lichtman J.H. Longenecker C.T. Loop M.S. Lutsey P.L. Martin S.S. Matsushita K. Moran A.E. Mussolino M.E. Perak A.M. Rosamond W.D. Roth G.A. Sampson U.K.A. Satou G.M. Schroeder E.B. Shah S.H. Shay C.M. Spartano N.L. Stokes A. Tirschwell D.L. VanWagner L.B. Tsao C.W. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2020 update: A report from the american heart association. Circulation 2020 141 9 e139 e596 10.1161/CIR.0000000000000757 31992061
    [Google Scholar]
  4. Yancy C.W. Jessup M. Bozkurt B. Butler J. Casey D.E. Jr Drazner M.H. Fonarow G.C. Geraci S.A. Horwich T. Januzzi J.L. Johnson M.R. Kasper E.K. Levy W.C. Masoudi F.A. McBride P.E. McMurray J.J.V. Mitchell J.E. Peterson P.N. Riegel B. Sam F. Stevenson L.W. Tang W.H.W. Tsai E.J. Wilkoff B.L. American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure. J. Am. Coll. Cardiol. 2013 62 16 e147 e239 10.1016/j.jacc.2013.05.019 23747642
    [Google Scholar]
  5. Cleland J.G.F. Daubert J.C. Erdmann E. Freemantle N. Gras D. Kappenberger L. Tavazzi L. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 2005 352 15 1539 1549 10.1056/NEJMoa050496 15753115
    [Google Scholar]
  6. Bristow M.R. Saxon L.A. Boehmer J. Krueger S. Kass D.A. De Marco T. Carson P. DiCarlo L. DeMets D. White B.G. DeVries D.W. Feldman A.M. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 2004 350 21 2140 2150 10.1056/NEJMoa032423 15152059
    [Google Scholar]
  7. Abraham W.T. Fisher W.G. Smith A.L. Delurgio D.B. Leon A.R. Loh E. Kocovic D.Z. Packer M. Clavell A.L. Hayes D.L. Ellestad M. Trupp R.J. Underwood J. Pickering F. Truex C. McAtee P. Messenger J. MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 2002 346 24 1845 1853 10.1056/NEJMoa013168 12063368
    [Google Scholar]
  8. Køber L. Thune J.J. Nielsen J.C. Haarbo J. Videbæk L. Korup E. Jensen G. Hildebrandt P. Steffensen F.H. Bruun N.E. Eiskjær H. Brandes A. Thøgersen A.M. Gustafsson F. Egstrup K. Videbæk R. Hassager C. Svendsen J.H. Høfsten D.E. Torp-Pedersen C. Pehrson S. DANISH Investigators Defibrillator implantation in patients with nonischemic systolic heart failure. N. Engl. J. Med. 2016 375 13 1221 1230 10.1056/NEJMoa1608029 27571011
    [Google Scholar]
  9. Doran B. Mei C. Varosy P.D. Kao D.P. Saxon L.A. Feldman A.M. DeMets D. Bristow M.R. The addition of a defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy. JACC Heart Fail. 2021 9 6 439 449 10.1016/j.jchf.2021.02.013 33992570
    [Google Scholar]
  10. Gu H. Sidhu B.S. Fang L. Webb J. Jackson T. Claridge S. Einarsen E. Razavi R. Papageorgiou N. Chow A. Bhattacharyya S. Chowienczyk P. Rinaldi C.A. First-phase ejection fraction predicts response to cardiac resynchronization therapy and adverse outcomes. JACC Cardiovasc. Imaging 2021 14 12 2275 2285 10.1016/j.jcmg.2021.05.007 34886993
    [Google Scholar]
  11. Jani C. Arora S. Zuzek Z. Jaswaney R. Thakkar S. Patel H.P. Lahewala S. Arora N. Josephson R. Deshmukh A. Viles-Gonzalez J. Osman M.N. Sahadevan J. Hoit B.D. Mackall J.A. Impact of catheter ablation in patients with atrial flutter and concurrent heart failure. Heart Rhythm O2 2020 2 1 53 63 10.1016/j.hroo.2020.11.005 34113905
    [Google Scholar]
  12. Sahashi Y. Kuno T. Tanaka Y. Passman R. Briasoulis A. Malik A.H. The 30-day readmission rate of same-day discharge protocol following catheter ablation for atrial fibrillation: A propensity score-matched analysis from National Readmission Database. Europace 2022 24 5 755 761 10.1093/europace/euab296 34904164
    [Google Scholar]
  13. Lam S.K.H. Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007 335 7626 925 928 10.1136/bmj.39343.511389.BE 17932160
    [Google Scholar]
  14. McMurray J.J.V. Packer M. Desai A.S. Gong J. Lefkowitz M.P. Rizkala A.R. Rouleau J.L. Shi V.C. Solomon S.D. Swedberg K. Zile M.R. PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014 371 11 993 1004 10.1056/NEJMoa1409077 25176015
    [Google Scholar]
  15. Nassif M.E. Windsor S.L. Tang F. Khariton Y. Husain M. Inzucchi S.E. McGuire D.K. Pitt B. Scirica B.M. Austin B. Drazner M.H. Fong M.W. Givertz M.M. Gordon R.A. Jermyn R. Katz S.D. Lamba S. Lanfear D.E. LaRue S.J. Lindenfeld J. Malone M. Margulies K. Mentz R.J. Mutharasan R.K. Pursley M. Umpierrez G. Kosiborod M. Malik A.O. Wenger N. Ogunniyi M. Vellanki P. Murphy B. Newman J. Hartupee J. Gupta C. Goldsmith M. Baweja P. Montero M. Gottlieb S.S. Costanzo M.R. Hoang T. Warnock A. Allen L. Tang W. Chen H.H. Cox J.M. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF trial. Circulation 2019 140 18 1463 1476 10.1161/CIRCULATIONAHA.119.042929 31524498
    [Google Scholar]
  16. McMurray J.J.V. Solomon S.D. Inzucchi S.E. Køber L. Kosiborod M.N. Martinez F.A. Ponikowski P. Sabatine M.S. Anand I.S. Bělohlávek J. Böhm M. Chiang C.E. Chopra V.K. de Boer R.A. Desai A.S. Diez M. Drozdz J. Dukát A. Ge J. Howlett J.G. Katova T. Kitakaze M. Ljungman C.E.A. Merkely B. Nicolau J.C. O’Meara E. Petrie M.C. Vinh P.N. Schou M. Tereshchenko S. Verma S. Held C. DeMets D.L. Docherty K.F. Jhund P.S. Bengtsson O. Sjöstrand M. Langkilde A.M. DAPA-HF Trial Committees and Investigators Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019 381 21 1995 2008 10.1056/NEJMoa1911303 31535829
    [Google Scholar]
  17. Packer M. Anker S.D. Butler J. Filippatos G. Pocock S.J. Carson P. Januzzi J. Verma S. Tsutsui H. Brueckmann M. Jamal W. Kimura K. Schnee J. Zeller C. Cotton D. Bocchi E. Böhm M. Choi D.J. Chopra V. Chuquiure E. Giannetti N. Janssens S. Zhang J. Gonzalez Juanatey J.R. Kaul S. Brunner-La Rocca H.P. Merkely B. Nicholls S.J. Perrone S. Pina I. Ponikowski P. Sattar N. Senni M. Seronde M.F. Spinar J. Squire I. Taddei S. Wanner C. Zannad F. EMPEROR-Reduced Trial Investigators Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 2020 383 15 1413 1424 10.1056/NEJMoa2022190 32865377
    [Google Scholar]
  18. Anker S.D. Butler J. Filippatos G. Ferreira J.P. Bocchi E. Böhm M. Brunner-La Rocca H.P. Choi D.J. Chopra V. Chuquiure-Valenzuela E. Giannetti N. Gomez-Mesa J.E. Janssens S. Januzzi J.L. Gonzalez-Juanatey J.R. Merkely B. Nicholls S.J. Perrone S.V. Piña I.L. Ponikowski P. Senni M. Sim D. Spinar J. Squire I. Taddei S. Tsutsui H. Verma S. Vinereanu D. Zhang J. Carson P. Lam C.S.P. Marx N. Zeller C. Sattar N. Jamal W. Schnaidt S. Schnee J.M. Brueckmann M. Pocock S.J. Zannad F. Packer M. EMPEROR-Preserved Trial Investigators Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 2021 385 16 1451 1461 10.1056/NEJMoa2107038 34449189
    [Google Scholar]
  19. Turakhia M.P. Cao M. Fischer A. Nabutovsky Y. Sloman L.S. Dalal N. Gold M.R. Reduced mortality associated with quadripolar compared to bipolar left ventricular leads in cardiac resynchronization therapy. JACC Clin. Electrophysiol. 2016 2 4 426 433 10.1016/j.jacep.2016.02.007 29759861
    [Google Scholar]
  20. Osca J. Alonso P. Cano O. Andrés A. Miro V. Tello M.J.S. Olagüe J. Martínez L. Salvador A. The use of multisite left ventricular pacing via quadripolar lead improves acute haemodynamics and mechanical dyssynchrony assessed by radial strain speckle tracking: Initial results. Europace 2016 18 4 560 567 10.1093/europace/euv211 26333378
    [Google Scholar]
  21. Wang C.L. Wu C.T. Yeh Y.H. Wu L.S. Chan Y.H. Kuo C.T. Chu P.H. Hsu L.A. Ho W.J. Left bundle-branch block contraction patterns identified from radial-strain analysis predicts outcomes following cardiac resynchronization therapy. Int. J. Cardiovasc. Imaging 2017 33 6 869 877 10.1007/s10554‑017‑1083‑5 28150083
    [Google Scholar]
  22. Katbeh A. Van Camp G. Barbato E. Galderisi M. Trimarco B. Bartunek J. Vanderheyden M. Penicka M. Cardiac resynchronization therapy optimization: A comprehensive approach. Cardiology 2019 142 2 116 128 10.1159/000499192 31117077
    [Google Scholar]
  23. Brunet-Bernard A. Maréchaux S. Fauchier L. Guiot A. Fournet M. Reynaud A. Schnell F. Leclercq C. Mabo P. Donal E. Combined score using clinical, electrocardiographic, and echocardiographic parameters to predict left ventricular remodeling in patients having had cardiac resynchronization therapy six months earlier. Am. J. Cardiol. 2014 113 12 2045 2051 10.1016/j.amjcard.2014.03.050 24793667
    [Google Scholar]
  24. Anand I.S. Carson P. Galle E. Song R. Boehmer J. Ghali J.K. Jaski B. Lindenfeld J. O’Connor C. Steinberg J.S. Leigh J. Yong P. Kosorok M.R. Feldman A.M. DeMets D. Bristow M.R. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: Results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation 2009 119 7 969 977 10.1161/CIRCULATIONAHA.108.793273 19204305
    [Google Scholar]
  25. Laish-Farkash A. Bruoha S. Katz A. Goldenberg I. Suleiman M. Michowitz Y. Shlomo N. Einhorn-Cohen M. Khalameizer V. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting. Europace 2017 19 8 1357 1363 10.1093/europace/euw349 27733457
    [Google Scholar]
  26. Hsu J.C. Solomon S.D. Bourgoun M. McNitt S. Goldenberg I. Klein H. Moss A.J. Foster E. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: The MADIT-CRT study. J. Am. Coll. Cardiol. 2012 59 25 2366 2373 10.1016/j.jacc.2012.01.065 22698490
    [Google Scholar]
  27. Russo A.M. Stainback R.F. Bailey S.R. Epstein A.E. Heidenreich P.A. Jessup M. Kapa S. Kremers M.S. Lindsay B.D. Stevenson L.W. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy. J. Am. Coll. Cardiol. 2013 61 12 1318 1368 10.1016/j.jacc.2012.12.017 23453819
    [Google Scholar]
  28. Schaer B.A. Osswald S. Di Valentino M. Soliman O.I. Sticherling C. ten Cate F.J. Jordaens L. Theuns D.A. Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy‐defibrillator patients. Eur. J. Heart Fail. 2010 12 12 1325 1332 10.1093/eurjhf/hfq171 20923856
    [Google Scholar]
  29. Boven N.V. Bogaard K. Ruiter J. Kimman G. Theuns D. Kardys I. Umans V. Functional response to cardiac resynchronization therapy is associated with improved clinical outcome and absence of appropriate shocks. J. Cardiovasc. Electrophysiol. 2013 24 3 316 322 10.1111/jce.12037 23210664
    [Google Scholar]
  30. Schrage B. Lund L.H. Melin M. Benson L. Uijl A. Dahlström U. Braunschweig F. Linde C. Savarese G. Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. Europace 2022 24 1 48 57 10.1093/europace/euab233 34486653
    [Google Scholar]
  31. Cevik C. Perez-Verdia A. Nugent K. Implantable cardioverter defibrillators and their role in heart failure progression. Europace 2009 11 6 710 715 10.1093/europace/eup091 19357142
    [Google Scholar]
  32. Kramer D.B. Normand S.L.T. Volya R. Hatfield L.A. Facility-level variation and clinical outcomes in use of cardiac resynchronization therapy with and without an implantable cardioverter-defibrillator. Circ. Cardiovasc. Qual. Outcomes 2018 11 12 e004763 10.1161/CIRCOUTCOMES.118.004763 30562069
    [Google Scholar]
  33. Çinier G. Hayıroğlu M.İ. Kolak Z. Tezen O. Yumurtaş A.Ç. Pay L. Eren S. Çetin T. Özcan S. Türkkan C. Özbilgin N. Tekkeşin A.İ. Alper A.T. Gürkan K. The value of C‐reactive protein‐to‐albumin ratio in predicting long‐term mortality among HFrEF patients with implantable cardiac defibrillators. Eur. J. Clin. Invest. 2021 51 8 e13550 10.1111/eci.13550 33778950
    [Google Scholar]
  34. Çinier G. Hayıroğlu M.İ. Pay L. Yumurtaş A.Ç. Tezen O. Eren S. Kolak Z. Çetin T. Özcan S. Türkkan C. Özbilgin N. Tekkeşin A.İ. Alper A.T. Gürkan K. Prognostic nutritional index as the predictor of long‐term mortality among HFrEF patients with ICD. Pacing Clin. Electrophysiol. 2021 44 3 490 496 10.1111/pace.14170 33438766
    [Google Scholar]
/content/journals/ccr/10.2174/011573403X345244250217052010
Loading
Trends in Readmissions Rates and Mortality after Cardiac Resynchronization Therapy in Patients with Nonischemic Cardiomyopathy
Bentham Science Publishers ; https://doi.org/10.2174/011573403X345244250217052010
/content/journals/ccr/10.2174/011573403X345244250217052010
/content/journals/ccr/10.2174/011573403X345244250217052010
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: mortality ; defibrillator ; readmissions ; cardiac resynchronization therapy ; Nonischemic cardiomyopathy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test